New Research on Astaxanthin and Cancer.
Although these studies were conducted in vitro (in a test tube or other culture media) and lab animals, the initial findings are so promising that there is hope that human applications will soon be confirmed.
Let's look at what this research is discovering.
What is Astaxanthin?
Astaxanthin is a xanthophyll carotenoid. (1) It is the vibrant red pigment that gives color to things like salmon, krill, arctic shrimp, and flamingo feathers. (2,3)
Numerous studies in animals have demonstrated the benefits of astaxanthin in eye health, skin health, heart health, liver health, and immune response, and several studies have assessed its safety, bioavailability, and effectiveness on oxidative stress in humans. (1,4)
Research findings from around the world are uncovering the ability of astaxanthin to combat cancer.
These studies show that astaxanthin has at least six different mechanisms of action that help combat cancer on multiple fronts. (5)
Six Ways Astaxanthin Defeats Cancer
1. Decreases Cancer Cell Proliferation.
Tumors develop when cancer cells rapidly proliferate, invade, migrate and adhere to healthy tissues and organs. (5,6) Astaxanthin is capable of decreasing proliferation of malignant cells.
In one study, investigators noted a strong association between the presence of astaxanthin and the decreased proliferation of rat liver- and breast-cancer cells, and of mouse lung-cancer cells.
It's interesting to note that a control group of normal human liver cells was barely affected by the presence of astaxanthin. (7) This indicates the ability of astaxanthin to selectively target cancer cells.
In another study, when astaxanthin was compared to the three other carotenoids (beta-carotene, capsanthin, and bixin), astaxanthin was found to be the most active in preventing the reproduction of human leukemic cells. (8)
2. Promotes Cell Death.
Programmed cell death, also known as apoptosis, is a healthy process in which the body removes damaged or dysfunctional cells. (9,10) A hallmark of cancer is its ability to evade apoptosis, which allows cancer cells to survive and reproduce. (11) One potent way to combat cancer is to turn this programmed cell death back on in cancer cells, and astaxanthin appears to do just that.
Astaxanthin has been shown to promote apoptosis in several in vitro studies involving cell lines of both oral and liver cancer (7,12,13)
3. Reduces Oxidative Stress.
Oxidative stress promotes by the growth and spread of certain types of cancers. (14,15)
Italian investigators found that astaxanthin stops the production of reactive oxygen species in a human lymphoma cell line. (16) Similarly, Chinese investigators noted that astaxanthin stifled the growth of human leukemia cells. (8)
4. Reduces Inflammation.
It is well known that inflammation plays a prominent role in cancer proliferation and survival. (17-19) Astaxanthin has been found to inhibit the occurrence of inflammatory mucosal ulcers and pockets. This led to the prevention of adenocarcinoma in the colons of mice. (20)
In other studies, astaxanthin suppressed the production of inflammation-inducing cytokines, including tumor necrosis factor alpha in human lymphoma cell lines. (16,21)
5. Prevents the Spread of Cancer.
The spread of cancer to other sites such as organs and bone (metastasis) occurs when cancer cells break away from the original tumor.
Enzymes known as matrix metalloproteinases (MMPs) facilitate a step in this complex process, allowing tumor cells to migrate to another organ where new growth takes place. (5,22,23) In other words, MMPs may promote tumor growth and progression.
Scientists believe that astaxanthin works to prevent the spread of cancer by inhibiting MMPs and modulating pathways related to tumor blood supply, cell proliferation, and cancer formation, progression and invasion. (24,25)
These protective effects have been demonstrated in oral-cancer cell lines from hamsters and in colon- and liver-cancer cell lines from rats. (24-26)
6. Improves Communication Among Cells.
Individual cells within an organ communicate with each other using gap-junction channels, structures which allow the coordination of metabolism and other critical functions. When there are defects in communication, it opens the door for disorders such as inflammation, cellular damage--and ultimately, cancer. (27-29)
Astaxanthin appears to support and enhance this form of cell-to-cell communication, which means it may be beneficial against a variety of different types of cancer.
For example, one investigator found that astaxanthin enhanced gap-junction communication, while noting that previous studies found that this enhanced communication has been shown to inhibit cancer formation and growth. (30)
Recent Studies on the Use of Astaxanthin in Cancer
Investigators in India recently examined the role of astaxanthin in stopping the growth and spread of oral cancer in hamsters.
To test this, researchers gave the animals a chemical designed to induce oral cancer, and then gave them either astaxanthin or no treatment. The investigators noted that the signaling pathways involved in the proliferation and spread of oral cancer were significantly inhibited in the cancer group that received astaxanthin. This included reducing the ability of tumor cells to create new blood vessels to fuel its growth (known as angiogenesis). These mechanisms demonstrate a potential value of astaxanthin to help treat oral cancer. (24)
As of 2012, liver cancer is the fifth most common cancer and the third most fatal cancer worldwide. (31,32) Despite modern treatments, liver cancer has a high recurrence rate, (33,34) which makes finding a new, effective treatment even more critical. Astaxanthin could be a step in that direction.
Investigators in China recently studied the use of astaxanthin in vitro in two cell lines of human hepatocellular carcinoma. They used several different concentrations of astaxanthin along with a control drug, dimethyl sulfoxide (DMSO). What they found was that astaxanthin induced a high level of cell death in both cell lines at three of these concentrations, leading investigators to conclude that astaxanthin is potentially useful in combatting this difficult-to-treat tumor. (35)
As of 2012, colorectal cancer is the third most common cancer in men and the second most common cancer in women worldwide. (36) Three important studies have shown astaxanthin's ability to combat colorectal cancer.
In the first study, investigators found that when they gave astaxanthin to rats with colorectal cancer, it significantly decreased the expressions of proteins consistent with inflammation and colorectal cancer, and significantly increased apoptosis (programmed cell death). (25)
In the second study, mice fed dietary astaxanthin experienced a decrease in the growth of cancer cells, and an increase in cell death. (20) And in a third study, astaxanthin inhibited cell growth of two colorectal cancer cell lines over a 72-hour period and caused cell-cycle arrest and cell death. (37)
Overall, these studies make it clear that astaxanthin has significant anti-inflammatory and anticancer effects in colorectal cancer.
Two promising lung cancer studies have recently shown that astaxanthin can help boost the effectiveness of standard cancer treatments.
In the first study, investigators treated human lung-cancer cell lines with either the chemotherapy drug pemetrexed, an astaxanthin solution, or both for 24 hours. The researchers found that combining the two agents (pemetrexed, and astaxanthin) improved cancer cell-killing and inhibited cancer cell growth. (38)
In a similar study, when investigators treated two human lung-cancer cell lines with astaxanthin solutions, they noted that astaxanthin reduced the viability of the cancer cells and decreased the production of proteins associated with chemotherapy resistance. Then, when astaxanthin was combined with equal amounts of the anticancer drug mitomycin C, the viability of the cancer cells decreased more than would be expected if either agent had been used separately.
The researchers concluded that not only may astaxanthin be useful on its own, but the combination of mitomycin C chemotherapy with astaxanthin could represent an effective method for improving the cancer cell-killing ability of this conventional treatment. (39)
Astaxanthin also shows promise in combatting one of the most common cancers in men: prostate cancer. In a recent study, investigators inoculated mice with human androgen-independent prostate cancer cells and then gave them either a high dose or a low dose of astaxanthin, or a placebo.
After just 31 days, tumor volume in the high-dose astaxanthin group was over 40% smaller than in the control group, and tumor weight was reduced by nearly 40%.
High-dose astaxanthin-treated mice also experienced a decrease in a tumor marker and in a marker of cell proliferation, as well as increases in the expression of tumor-suppressor genes. (40)
The investigators concluded that the use of astaxanthin may prove beneficial in the treatment of prostate cancer. (40)
Astaxanthin is being studied in vitro and in animals against a variety of animal- and human-cancer cell lines.
At least six possible mechanisms of action have been put forward to explain astaxanthin's anticancer effects.
In addition to its standalone anticancer properties, two studies demonstrated astaxanthin's role in increasing the effectiveness of cytotoxic chemotherapy.
These initial findings offer hope that astaxanthin could play a significant role in combatting some of the most common forms of cancer, including solid tumors and hematologic malignancies like leukemia.
If you have any questions on the scientific content of this article, please call a Life Extension[R] Wellness Specialist at 1-866-864-3027.
(1.) Guerin M, Huntley ME, Olaizola M. Haematococcus astaxanthin: applications for human health and nutrition. Trends Biotechnol. 2003;21(5):210-6.
(2.) Choi S, Koo S. Efficient syntheses of the keto-carotenoids canthaxanthin, astaxanthin, and astacene. J Org Chem. 2005;70(8):3328-31.
(3.) Hussein G, Sankawa U, Goto H, et al. Astaxanthin, a carotenoid with potential in human health and nutrition. J Nat Prod. 2006;69(3):443-9.
(4.) Fassett RG, Coombes JS. Astaxanthin, oxidative stress, inflammation and cardiovascular disease. Future Cardiol. 2009;5(4):333-42.
(5.) Zhang L, Wang H. Multiple Mechanisms of Anti-Cancer Effects Exerted by Astaxanthin. Mar Drugs. 2015;13(7):4310-30.
(6.) Available at: https://www.ncbi.nlm.nih.gov/books/NBK9963/. Accessed August 22, 2017.
(7.) Song XD, Zhang JJ, Wang MR, et al. Astaxanthin induces mitochondria-mediated apoptosis in rat hepatocellular carcinoma CBRH-7919 cells. Biol Pharm Bull. 2011;34(6):839-44.
(8.) Zhang X, Zhao WE, Hu L, et al. Carotenoids inhibit proliferation and regulate expression of peroxisome proliferators-activated receptor gamma (PPARgamma) in K562 cancer cells. Arch Biochem Biophys. 2011;512(1):96-106.
(9.) Lo AC, Woo TT, Wong RL, et al. Apoptosis and other cell death mechanisms after retinal detachment: implications for photoreceptor rescue. Ophthalmologica. 2011;226 Suppl 1:10-7.
(10.) Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495-516.
(11.) Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell. 100(1):57-70.
(12.) Song X, Wang M, Zhang L, et al. Changes in cell ultrastructure and inhibition of JAK1/STAT3 signaling pathway in CBRH-7919 cells with astaxanthin. Toxicol Mech Methods. 2012;22(9):679-86.
(13.) Kavitha K, Kowshik J, Kishore TK, et al. Astaxanthin inhibits NF-kappaB and Wnt/beta-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer. Biochim Biophys Acta. 2013;1830(10):4433-44.
(14.) Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85-95.
(15.) Glasauer A, Chandel NS. Targeting antioxidants for cancer therapy. Biochem Pharmacol. 2014;92(1):90-101.
(16.) Franceschelli S, Pesce M, Ferrone A, et al. Astaxanthin treatment confers protection against oxidative stress in U937 cells stimulated with lipopolysaccharide reducing O2- production. PLoS One. 2014;9(2):e88359.
(17.) Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860-7.
(18.) Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436-44.
(19.) Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441(7092):431-6.
(20.) Yasui Y, Hosokawa M, Mikami N, et al. Dietary astaxanthin inhibits colitis and colitis-associated colon carcinogenesis in mice via modulation of the inflammatory cytokines. Chem Biol Interact. 2011;193(1):79-87.
(21.) Speranza L, Pesce M, Patruno A, et al. Astaxanthin treatment reduced oxidative induced pro-inflammatory cytokines secretion in U937: SHP-1 as a novel biological target. Mar Drugs. 2012;10(4):890-9.
(22.) van Zijl F, Krupitza G, Mikulits W. Initial steps of metastasis: Cell invasion and endothelial transmigration. Mutation Research/Reviews in Mutation Research. 2011;728(1-2):23-34.
(23.) Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3(6):453-8.
(24.) Kowshik J, Baba AB, Giri H, et al. Astaxanthin inhibits JAK/STAT-3 signaling to abrogate cell proliferation, invasion and angiogenesis in a hamster model of oral cancer. PLoS One. 2014;9(10):e109114.
(25.) Nagendraprabhu P, Sudhandiran G. Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NFkB and COX-2. Invest New Drugs. 2011;29(2): 207-24.
(26.) Kozuki Y, Miura Y, Yagasaki K. Inhibitory effects of carotenoids on the invasion of rat ascites hepatoma cells in culture. Cancer Lett. 2000;151(1):111-5.
(27.) Castellano P, Eugenin EA. Regulation of gap junction channels by infectious agents and inflammation in the CNS. Front Cell Neurosci. 2014;8:122.
(28.) Willecke K, Eiberger J, Degen J, et al. Structural and functional diversity of connexin genes in the mouse and human genome. Biol Chem. 2002;383(5):725-37.
(29.) Mesnil M, Crespin S, Avanzo J-L, et al. Defective gap junctional intercellular communication in the carcinogenic process. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2005;1719(1-2):125-45.
(30.) Hix LM, Lockwood SF, Bertram JS. Upregulation of connexin 43 protein expression and increased gap junctional communication by water soluble disodium disuccinate astaxanthin derivatives. Cancer Lett. 2004;211(1):25-37.
(31.) Available at: http://globocan.iarc.fr/old/FactSheets/cancers/liver-new.asp. Accessed August 23, 2017.
(32.) Wong MC, Jiang JY, Goggins WB, et al. International incidence and mortality trends of liver cancer: a global profile. Sci Rep. 2017;7:45846.
(33.) Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243(2):229-35.
(34.) Soong RS, Yu MC, Chan KM, et al. Analysis of the recurrence risk factors for the patients with hepatocellular carcinoma meeting University of California San Francisco criteria after curative hepatectomy. World J Surg Oncol. 2011;9:9.
(35.) Li J, Dai W, Xia Y, et al. Astaxanthin Inhibits Proliferation and Induces Apoptosis of Human Hepatocellular Carcinoma Cells via Inhibition of Nf-Kappab P65 and Wnt/Beta-Catenin in Vitro. Mar Drugs. 2015;13(10):6064-81.
(36.) Available at: http://globocan.iarc.fr/old/FactSheets/cancers/colorectal-new.asp. Accessed August 23, 2017.
(37.) Liu X, Song M, Gao Z, et al. Stereoisomers of Astaxanthin Inhibit Human Colon Cancer Cell Growth by Inducing G2/M Cell Cycle Arrest and Apoptosis. J Agric Food Chem. 2016.
(38.) Liao KS, Wei CL, Chen JC, et al. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells. Regul Toxicol Pharmacol. 2016;81:353-61.
(39.) Ko JC, Chen JC, Wang TJ, et al. Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cells. Biochem Pharmacol. 2016;105:91-100.
(40.) Ni X, Yu H, Wang S, et al. Astaxanthin Inhibits PC-3 Xenograft Prostate Tumor Growth in Nude Mice. Mar Drugs. 2017;15(3).
By Jack H. Raber, Pharm.D.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||RESEARCH UPDATE|
|Author:||Raber, Jack H.|
|Date:||Dec 1, 2017|
|Next Article:||Pea Protein.|